As of his latest scan in November, 18 months post surgery, Scolyer's cancer hasn't recurred [1]. Average time to recurrence post-surgery is 6 months.

Don't want to leap to conclusions prematurely, but that might be some progress.

[1] https://x.com/ProfRAScolyer/status/1859179205885673877

▲

adamredwoods a year ago | parent [-]

He tried an experimental payload that contained two ADCs, one BRAF inhibitor and something else, maybe PD-1 inhibitor. Then he had surgery. Payload-heavy ADCs are the way forward against difficult cancers.

	▲	Pakrozee a year ago \| parent [-]
		They're using weakened viruses. Virus use in cancer is nothing new, but an interesting field. I can see why pharma hesitates using it, viruses can mutate, too, similar to cancer. https://pakrozee.pk/